Christopher Jahn

Christopher Jahn

Auto-generated profile, based on publicly available information

Christopher Jahn

Institute of Molecular and Translational Therapeutic Strategies, Hannover Medical School, Hannover, Germany

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 November 2021 in Scientific Reports
Verified
Journal Article
Open access
PDF file
REReto Eggenschwiler
Reto Eggenschwiler
TGThomas Gschwendtberger
Thomas Gschwendtberger
CFChristian Felski
Christian Felski
CJChristopher Jahn
Christopher Jahn
FLFlorian Langer
Florian Langer
Tobias CantzTobias Cantz
Tobias Cantz
CRISPR prime-editors are emergent tools for genome editing and offer a versatile alternative approach to HDR-based genome engineering or DNA base-editors. However, sufficient prime-editor expression levels and availability of optimized transfection protocols may affect editing efficiencies, especially in hard-to-transfect cells like hiPSC. Here, we show that piggyBac prime-editing (PB-PE) allows for sustained expression of prime-editors. We demonstrate proof-of-concept for PB-PE in a newly designed lentiviral traffic light reporter, which allows for estimation of gene correction and defective editing resulting in indels, based on expression of two different fluorophores. PB-PE can prime-edit more than 50% of hiPSC cells after antibiotic selection. We also show that improper design of pegRNA cannot simply be overcome by extended expression, but PB-PE allows for estimation of effectiveness of selected pegRNAs after few days of cultivation time. Finally, we implemented PB-PE for efficient editing of an amyotrophic lateral sclerosis-associated mutation in the SOD1-gene of patient-derived hiPSC. Progress of genome editing can be monitored by Sanger-sequencing, whereas PB-PE vectors can be removed after editing and excised cells can be enriched by fialuridine selection. Together, we present an efficient prime-editing toolbox, which can be robustly used in a variety of cell lines even when non-optimized transfection-protocols are applied.

30 May 2019 in Cardiovascular Research
Verified
Journal Article
Closed access
CJChristopher Jahn
Christopher Jahn
CBChristian Bär
Christian Bär
Thomas ThumThomas Thum
Thomas Thum

5 December 2025 in bioRxiv
Verified
Preprint
Open access
MJMalte Juchem
Malte Juchem
SESedef Ersoy
Sedef Ersoy
LOLea Oehlsen
Lea Oehlsen
JYJia Li Ye
Jia Li Ye
NWNatalie Weber
Natalie Weber
Thomas ThumThomas Thum
Thomas Thum
The lysosomal storage disorder Fabry disease results from α-galactosidase A deficiency, leading to excessive glycosphingolipid substrate accumulation, primarily globotriaosylceramide (Gb3). While the underlying molecular mechanisms remain elusive, multi-systemic complications ultimately culminate in premature death, with heart failure being the leading cause of death. Current treatment options fail to treat Fabry disease adequately and only delay its progression. Preclinical studies on an alternative approach, systemic delivery of nucleoside-modified GLA mRNA (modGLA), suggest improved effectiveness over existing therapies in reducing glycosphingolipid levels in the heart. It remains unclear whether modGLA can rescue Fabry cardiomyopathy phenotypes at the cellular level, which are not faithfully recapitulated in current animal models. To address this, we investigated characteristic phenotypes in two new models of Fabry cardiomyopathy utilizing human iPSC-derived cardiomyocytes in transcriptomic and functional analyses. These human Fabry disease cardiomyocytes displayed broad transcriptional dysregulation, apoptosis, mitochondrial dysfunction, impaired reactive oxygen species handling, as well as enhanced decay parameters of calcium transients. Mechanistically, we identified hyperphosphorylated phospholamban as a major player in this calcium dysregulation. Strikingly, modGLA therapy of Fabry cardiomyocytes restored α-galactosidase A enzyme activity, reduced glycosphingolipid deposition, and normalized the observed molecular alterations, supporting modGLA therapy as a promising strategy for the treatment of Fabry disease.

17 August 2026 in Stem Cell Research
Verified
Journal Article
Open access
NHNick Heise
Nick Heise
CBCarla Nunes Paulino Borisch
Carla Nunes Paulino Borisch
CJChristopher Jahn
Christopher Jahn
KSKristina Sonnenschein
Kristina Sonnenschein
NDNataliya Di Donato
Nataliya Di Donato
MJMalte Juchem
Malte Juchem
Fabry disease (FD) is a monogenic, X-linked lysosomal storage disorder originating from mutations in the GLA gene, which encodes alpha-galactosidase A. Impaired enzyme activity leads to accumulation of the substrate globotriaosylceramide (Gb3) and a multisystemic phenotype. Here, we generated two human induced pluripotent stem cell (hiPSC) lines from a female FD patient carrying a heterozygous c.644A > G missense mutation. The hiPSCs displayed normal karyotype, typical morphology, trilineage differentiation capacity and expressed markers of undifferentiated hPSC state. Consequently, MHHi043-A and MHHi043-B provide a valuable resource for studying FD mechanisms and developing therapeutic strategies.